Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Outpatient at least 12 years of age
Both genders; females of childbearing potential must be willing to use birth control method
Clinical diagnosis of asthma for ≥12 weeks
Best pre-bronchodilator FEV1 of 40%-90% predicted
Reversibility of FEV1 of at least 12% and 200mls
Current asthma therapy that include an inhaled corticosteroid for at least 12 weeks prior to 1st visit
Ability to use replace current short-acting rescue treatment with albuterol and ability to withhold albuterol use for at least 6 hours prior to study visits
You may not be if
History of life-threatening asthma
Respiratory infection within last 4 weeks leading to change in asthma management
Asthma exacerbation within last 3 months
Concurrent respiratory disease or other disease that would confound study participation or affect subject safety
Allergies to study drugs, study drugs' excipients, or medications related to study drugs
Taking another investigational medication or medication prohibited for use during the study.
Previous participation in a vilanterol (GW642444) study
Clareo Health | Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
